163 related articles for article (PubMed ID: 16815317)
1. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
Le Meur Y; Djebli N; Szelag JC; Hoizey G; Toupance O; Rérolle JP; Marquet P
Clin Pharmacol Ther; 2006 Jul; 80(1):51-60. PubMed ID: 16815317
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Habuchi T; Suzuki T
Steroids; 2008 Oct; 73(11):1052-9. PubMed ID: 18502461
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.
Renders L; Frisman M; Ufer M; Mosyagin I; Haenisch S; Ott U; Caliebe A; Dechant M; Braun F; Kunzendorf U; Cascorbi I
Clin Pharmacol Ther; 2007 Feb; 81(2):228-34. PubMed ID: 17192769
[TBL] [Abstract][Full Text] [Related]
5. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.
Wang HF; Qiu F; Wu X; Fang J; Crownover P; Korth-Bradley J; Schulman S
Clin Pharmacol Drug Dev; 2014 May; 3(3):235-41. PubMed ID: 27128614
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
Yates CR; Zhang W; Song P; Li S; Gaber AO; Kotb M; Honaker MR; Alloway RR; Meibohm B
J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
[TBL] [Abstract][Full Text] [Related]
8. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
Miao LY; Huang CR; Hou JQ; Qian MY
Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
[TBL] [Abstract][Full Text] [Related]
9. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
[TBL] [Abstract][Full Text] [Related]
11. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
Lee J; Huang H; Chen Y; Lu X
Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
16. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
Lloberas N; Torras J; Cruzado JM; Andreu F; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Brunet M; Ekberg H; Grinyó JM;
Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
